Results 111 to 120 of about 59,797 (283)

Movement Disorders Associated with 22q11.2 Microdeletion: A Scoping Review

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Movement disorders have recently emerged as important neurologic manifestations of the 22q11.2 microdeletion that affects nearly one in every 2000 live births. Objective We aimed to map the existing evidence regarding the spectrum, diagnosis and treatment, and etiopathogenesis of movement disorders associated with 22q11.2 ...
Nikolai Gil D. Reyes, Daniel G. Di Luca, Connie Marras, Erik Boot, Ryan K.C. Yuen, Anthony E. Lang, Anne S. Bassett   +6 more
wiley   +1 more source

Affinities and intrinsic activities of dopamine receptor agonists for the hD(21) and hD(4.4) receptors

, 1996
The affinity and intrinsic activity of dopamine receptor agonists were determined at the human dopamine hD(21) and hD(4.4) receptors. (-)-3-Hydroxy-N-n-propylpiperidine ((-)3-PPP) had an intrinsic activity of 46% and 83%, whereas (+)-N ...
Lahti, RA, Tepper, PG, Cochrane, EV, Mutin, A, Wikstrom, H, Dijkstra, D, Tamminga, CA   +6 more
core   +2 more sources

Dopamine agonists, receptor selectivity and dyskinesia induction in Parkinson's disease

, 2003
Levodopa and the dopamine agonists are effective symptomatic treatments for Parkinson's disease, and all patients receive at least one of these agents during their illness. Long-term use of levodopa is commonly associated with motor complications such as
Jenner, P
core  

Medication Knowledge of Patients with Parkinson's Disease: Strengths and Gaps

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Effective drug treatment of motor and non‐motor symptoms in Parkinson's disease (PD) often requires the administration of several anti‐Parkinson drugs in complex treatment regimens. The successful autonomous application of drugs places high demands on therapy adherence, which in turn relies on sufficient medication knowledge ...
Stephan Greten, Sarana Ulaganathan, Johannes Heck, Lan Ye, Matthias Höllerhage, Christoph Schrader, Corinna Ziemann, Olaf Krause, Florian Wegner, Martin Klietz   +9 more
wiley   +1 more source

Considerations for Initiation and Maintenance of Foslevodopa/Foscarbidopa for Advanced Parkinson's Disease

Movement Disorders Clinical Practice, EarlyView.
Abstract Background As Parkinson's disease (PD) progresses, motor fluctuations become increasingly difficult to manage with oral medications. Foslevodopa/foscarbidopa (LDp/CDp), delivered as a continuous 24‐h/day subcutaneous infusion, offers continuous levodopa delivery and stable plasma levodopa levels that reduce motor fluctuations. LDp/CDp has been
K. Ray Chaudhuri, Bruno Bergmans, Eric Freire‐Alvarez, Lucie Hopes, Drew S. Kern, Robert S. Kirsner, Giulia Lazzeri, Pedro Mendes‐Bastos, Noriko Nishikawa, Per Odin, Karolina Poplawska‐Domaszewicz, Rajesh Pahwa, Yuval Ramot, Klaus Seppi, Tobias Warnecke, Robert Wiggins, Megha B. Shah, Pavnit Kukreja, Bjoern Fritz, Koray Onuk, Stuart H. Isaacson   +20 more
wiley   +1 more source

Pharmacological evaluation of some alpha-adrenoceptor and dopamine receptor agonists [PDF]

, 1984
This thesis describes the investigations that have been performed in order to assess the pharmacological properties of some putative dopamine receptor agonists. ...
Oene, Johannes Cornelis van,, Oene, Johannes Cornelis van   +1 more
core  

Resistance to dopamine agonists in prolactinoma is correlated with reduction of dopamine D2 receptor long isoform mRNA levels

, 2012
ObjectiveDopamine agonists normalize prolactin (PRL) levels and reduce tumour size in responsive prolactinoma. However, several cases have shown resistance to dopamine agonists upon initial treatment.
Satoko Shimazu, Shozo Yamada, Naoko Inoshita, Yuko Nagamura, Toshihiko Tsukada, Akira Shimatsu, Takeshi Usui   +6 more
core   +1 more source

Crossing the Blood–Brain Barrier: Molecular Imaging Illuminates Transplanted Stem Cells in the Brain

iRADIOLOGY, EarlyView.
Peili Cen, Yan Zhong, Rui Zhou, Jing Wang, Han Jiang, Mei Tian, Hong Zhang   +6 more
wiley   +1 more source

Continuous Subcutaneous Versus Intestinal Levodopa Infusion for Parkinson's Disease: A Real‐World, Monocentric, Observational Study and Critical Review

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Subcutaneous foslevodopa‐foscarbidopa (SCFF) is a novel, non‐surgical dopaminergic infusion therapy for better controlling motor fluctuations in advanced Parkinson's disease (PD). However, there are scarce real‐world data on efficacy, adverse events and comparisons with other infusion strategies. Objectives Here, we aimed to provide
Johannes Hartig, Lennert Sitzmann, Doreen Hartenstein, Marion Labisch, Chi Wang Ip, Jens Volkmann, Christine Daniels   +6 more
wiley   +1 more source

Hypotensive Episodes Precede Cognitive Fluctuations in Parkinson's Disease Dementia

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Cognitive fluctuations (CFs) are a disabling feature in Parkinson's disease dementia (PDD) and contribute to caregiver burden. The relationship between CFs and neurogenic orthostatic hypotension (nOH), a common autonomic complication in PDD, has not been adequately examined.
Jorge Patino, Kevin Duque, Jesus Abanto, Aaron Bloemer, Heba Deraz, Alberto J. Espay, Abhimanyu Mahajan   +6 more
wiley   +1 more source